Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

ceivables, net (including unbilled receivables)2,343,9874,317,170Prepaid expenses and other current assets470,6661,014,002Assets held for sale976,6001,000,100Total current assets18,337,03023,583,729Property and equipment, net900,9261,178,416Other long-term assets and deferred costs53,38488,447Goodwill2,348,4532,348,453Total assets$

21,639,793$

27,199,045LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$

445,515$

3,128,203Accrued expenses and other liabilities3,245,9903,035,284Total current liabilities3,691,5056,163,487Other long-term liabilities454,093461,858Derivative instruments2,956,0808,362,995Total liabilities7,101,67814,988,340Stockholders' equity:Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,194,035 and 46,238,244 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively4,8194,624Additional paid-in-capital207,810,326200,847,468Accumulated other comprehensive income1,161,6201,250,497Accumulated deficit(194,438,650)(189,891,884)Total stockholders'
equity14,538,11512,210,705Total liabilities and stockholders' equity$

21,639,793$

27,199,045PHARMATHENE, INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree months endedSeptember 30,Nine months endedSeptember 30,2011201020112010Contract revenue$

5,260,057$

6,243,567$

18,026,619$

14,139,711Operating expenses:Research and development4,884,2316,172,14716,688,70317,064,900General and administrative3,283,2463,177,88811,632,27212,625,132Depreciation and amortization114,494258,231348,813757,929Total operating expenses8,281,9719,608,26628,669,78830,447,961Loss from operations(3,021,914)(3,364,699)(10,643,169)(16,308,250)Other income (expenses):Interest income3,96118410,4966,249Interest expense(9,932)(946,023)(40,540)(2,815,638)Other income (expense)95,520(93,260)50,89275,914Change in market value of derivative instruments2,898,86975,5946
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
7. PharmAthene Completes $6.5 Million Registered Direct Offering
8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... YORK , September 2, 2014 ... Study on Membrane Technology in Pharmaceutical, Biopharma and Life ... Highest Growth by 2019" the global membrane technology market for pharmaceutical, ... million in 2014 and is expected to grow at ... reach an estimated value of USD 10,886.0 million in ...
(Date:9/2/2014)... DIEGO , Sept. 2, 2014 Orexigen ... that the U.S. Patent and Trademark Office (PTO) has ... medication being evaluated for weight loss. NB32 is a ... SR. U.S. Patent No. 8,815,889 claims methods ... and bupropion. The patent expires in 2024. If NB32 ...
(Date:9/2/2014)... NC (PRWEB) September 02, 2014 ... of its 11th clinical research site: PMG Research of ... ownership and operation of the clinical research department at ... expanding PMG’s presence in eastern North Carolina. This new ... For the patients in Rocky Mount and the surrounding ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 The ... $1,712.1 million by 2019 from $1,070.7 million in ... 2014 to 2019. The global oligonucleotide synthesis market ... services, applications, end users, and geography. The synthesized ... growth rate in the oligonucleotide synthesis market during ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... advanced tools after their brains evolved a greater capacity for ... it took early humans almost two million years to move ... used computer modelling and tiny sensors embedded in gloves to ... order to make two types of tools during the Lower ...
... 2010Scientists at the U.S. Department of Energy,s Los Alamos ... thin films capable of absorbing light and generating electric ... in the journal Chemistry of Materials, could ... "Potentially, with future refinement of this technology, windows in ...
... Colo., Nov. 3, 2010 Bolder BioTechnology, Inc. today ... $1.2 million in Qualifying Therapeutic Discovery Project Grants.  Grants ... Discovery Project Tax Credit Program, which authorized up to ... companies with 250 or fewer employees.   ...
Cached Biology Technology:Stone Age humans needed more brain power to make big leap in tool design 2Scientists produce transparent, light-harvesting material 2Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants 2
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/2/2014)... people take stress in stride; others are done in ... the molecular mechanisms of this so-called stress gap in ... that could lead researchers to better understand the development ... "Like people, each animal has unique experiences as it ... life experiences can alter the expression of genes, and ...
(Date:9/1/2014)... ─ Dietary quality in the U.S. has improved steadily ... fat intakebut overall dietary quality remains poor and disparities ... to a new study from Harvard School of Public ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... British Columbia researchers are part of an international team ... a step they hope will lead to a universal ... conservation efforts. Barcodes based on portions of DNA ... have already emerged as a viable solution for ...
... The most comprehensive analysis yet of the genome of childhood ... the genetic blueprint, suggesting the cancer arises from just a ... Children,s Research Hospital. The research appears in the July 27 ... of Sciences . "Our data raise the ...
... BOSTONThe androgen receptor a protein ignition switch ... a master of adaptability. When drug therapy deprives the ... receptor manages to find an alternate growth route. A ... University scientists demonstrates how. The shift from androgen-dependent to ...
Cached Biology News:UBC researchers help push for standard DNA barcodes for plants 2Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 2Comprehensive look at rare leukemia finds relatively few genetic changes launch disease 3Study reveals a reprogrammed role for the androgen receptor 2
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
... Neogens enzyme-linked immunosorbent assay (ELISA) ... as screening devices for the detection of ... The kits are intended for forensic use ... samples be confirmed by a quantitative method ...
... SUPERaseIn RNase Inhibitor (patent pending) is ... that noncovalently binds and inhibits the most ... B, C, 1 and T1. SUPERaseIn can ... contamination could be problematic. It is ideal ...
Biology Products: